Pursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws, and in accordance with the Regulation 30 read with Para B of Part A of Schedule III of the Listing Regulations and SEBI circular dated July 13, 2023 SEBI Listing Regulations, Supriya Lifescience has informed that the investigation has been initiated yesterday against Sreekant Sreedharan, General Manager, Sales & Marketing officer of the Company by Special Investigation and Intelligence branch of Customs Department, subsequent to which judicial custody has been granted by CMM court till July 17, 2026. The Company remains committed to maintaining the highest standards of corporate governance and regulatory compliance. The Company is closely monitoring the developments in the case and any further material developments in the matter shall be disclosed to the stock exchanges in accordance with applicable laws and regulations. The details of the case as required under Circular no SEBI/HO/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are enclosed as Annexure A to the disclosure.
The above information is a part of company’s filings submitted to BSE.
